NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.
This activity is designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for CLL/SLL
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for CLL/SLL
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.
Kimberly Callan, MS, Senior Director, Professional and Patient Publications, NCCN, has disclosed that she has no relevant financial relationships.
Genevieve Hartzman, MA, Journal Production Specialist, NCCN, has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships. (Employed by NCCN until 2/17/17)
Karen Kanefield, Manager, Continuing Education Accreditation and Program Operations, has disclosed that she has no relevant financial relationships.
Kathy Smith, Manager, CE Grant Writing & Project Management, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
William G. Wierda, MD, PhD, Panel Vice Chair, has disclosed that he receives consulting fees/honoraria from AbbVie Inc.; Acerta Pharma; Celgene Corporation; Emergent BioSolutions Inc.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics; Roche Laboratories, Inc.; and sanofi-aventis U.S. He receives grant/research support from and is a scientific advisor for AbbVie Inc.; Acerta Pharma; Emergent BioSolutions Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm; Novartis Pharmaceuticals Corporation; Pharmacyclics; and Roche Laboratories, Inc. He is a scientific advisor for sanofi-aventis U.S., Celgene Corporation, Genzyme Corporation, and Merck & Co., Inc.; and he receives grant/research support from Juno Therapeutics and Kite Pharma.
Andrew D. Zelenetz, MD, PhD, Panel Chair, has disclosed he receives consulting fees/honoraria from Amgen Inc.; Axess Oncology; Celgene Corporation; Gilead Sciences, Inc.; GlaxoSmithKline; Hospira; Janssen Pharmaceutica Products, LP; Medscape, LLC; Roche Laboratories, Inc.; Takeda Pharmaceuticals North America, Inc.; and The France Foundation. He also receives grant/research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; and Roche Laboratories, Inc.
Leo I. Gordon, MD, Panel Vice Chair, has disclosed that he has no relevant financial relationships.
Thomas M. Habermann, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships.
Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-003-H01-P
All clinicians completing this activity will be issued a certificate of participation.
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation